| Assessment Status |
Assessment process complete |
| HTA ID |
- |
| Drug |
Sufentanil |
| Brand |
Zalviso® |
| Indication |
For the management of acute moderate to severe post-operative pain in adult patients. |
| Rapid review commissioned |
14/03/2016 |
| Rapid review completed |
22/03/2016 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE |
16/08/2017 |
| Pre-submission consultation with Applicant |
24/05/2017 |
| Full submission received from Applicant |
31/10/2017 |
| Additional follow-up to Preliminary Review sent to Applicant |
15/06/2018 |
| NCPE assessment outcome |
The assessment of sufentanil (Zalviso®) has been discontinued as the company has made a decision not to commercialise sufentanil in Ireland. 27/06/2018 |
